Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.

Bach P, Boström J, Brickmann K, van Giezen JJ, Hovland R, Petersson AU, Ray A, Zetterberg F.

Bioorg Med Chem Lett. 2011 May 15;21(10):2877-81. doi: 10.1016/j.bmcl.2011.03.088. Epub 2011 Mar 30.

PMID:
21507636
[PubMed - indexed for MEDLINE]
2.

Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.

Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4657-63. doi: 10.1016/j.bmcl.2009.06.075. Epub 2009 Jun 25.

PMID:
19604694
[PubMed - indexed for MEDLINE]
3.

Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.

Hao M, Li Y, Wang Y, Yan Y, Zhang S, Li G, Yang L.

J Chem Inf Model. 2011 Oct 24;51(10):2560-72. doi: 10.1021/ci2002878. Epub 2011 Sep 29. Erratum in: J Chem Inf Model. 2011 Nov 28;51(11):3027. Li, Guohui [added]; Yang, Ling [added].

PMID:
21923153
[PubMed - indexed for MEDLINE]
4.

Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.

Bach P, Boström J, Brickmann K, van Giezen JJ, Groneberg RD, Harvey DM, O'Sullivan M, Zetterberg F.

Eur J Med Chem. 2013 Jul;65:360-75. doi: 10.1016/j.ejmech.2013.04.007. Epub 2013 May 15.

PMID:
23747805
[PubMed - indexed for MEDLINE]
5.

Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.

Zech G, Hessler G, Evers A, Weiss T, Florian P, Just M, Czech J, Czechtizky W, Görlitzer J, Ruf S, Kohlmann M, Nazaré M.

J Med Chem. 2012 Oct 25;55(20):8615-29. doi: 10.1021/jm300771j. Epub 2012 Oct 4.

PMID:
22984835
[PubMed - indexed for MEDLINE]
6.

Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.

Zhang H, Liu J, Zhang L, Kong L, Yao H, Sun H.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3598-602. doi: 10.1016/j.bmcl.2012.04.050. Epub 2012 Apr 16.

PMID:
22546677
[PubMed - indexed for MEDLINE]
7.

II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.

Shao Y, Anilkumar GN, Carroll CD, Dong G, Hall JW 3rd, Hobbs DW, Jiang Y, Jenh CH, Kim SH, Kozlowski JA, McGuinness BF, Rosenblum SB, Schulman I, Shih NY, Shu Y, Wong MK, Yu W, Zawacki LG, Zeng Q.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1527-31. doi: 10.1016/j.bmcl.2010.12.114. Epub 2010 Dec 28.

PMID:
21277198
[PubMed - indexed for MEDLINE]
8.

Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2.

Hudson S, Kiankarimi M, Rowbottom MW, Vickers TD, Wu D, Pontillo J, Ching B, Dwight W, Goodfellow VS, Schwarz D, Heise CE, Madan A, Wen J, Ban W, Wang H, Wade WS.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4922-30. Epub 2006 Jul 7.

PMID:
16824755
[PubMed - indexed for MEDLINE]
9.

Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.

Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD.

J Med Chem. 2010 Mar 11;53(5):2010-37. doi: 10.1021/jm901518t.

PMID:
20141147
[PubMed - indexed for MEDLINE]
10.

BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.

Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, Liu J, Zhang X, Kunapuli SP, Ding Z.

Thromb Haemost. 2010 Oct;104(4):845-57. doi: 10.1160/TH10-05-0285. Epub 2010 Aug 30.

PMID:
20806121
[PubMed - indexed for MEDLINE]
11.

Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.

Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1388-94. doi: 10.1016/j.bmcl.2009.12.110. Epub 2010 Jan 4.

PMID:
20097563
[PubMed - indexed for MEDLINE]
12.

Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.

Morera E, De Petrocellis L, Morera L, Moriello AS, Ligresti A, Nalli M, Woodward DF, Di Marzo V, Ortar G.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6806-9. doi: 10.1016/j.bmcl.2009.09.033. Epub 2009 Oct 20.

PMID:
19875281
[PubMed - indexed for MEDLINE]
13.
14.

Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1.

Rowbottom MW, Vickers TD, Dyck B, Grey J, Tamiya J, Zhang M, Kiankarimi M, Wu D, Dwight W, Wade WS, Schwarz D, Heise CE, Madan A, Fisher A, Petroski R, Goodfellow VS.

Bioorg Med Chem Lett. 2006 Sep 1;16(17):4450-7. Epub 2006 Jun 30.

PMID:
16814542
[PubMed - indexed for MEDLINE]
15.

N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.

Batt DG, Houghton GC, Roderick J, Santella JB 3rd, Wacker DA, Welch PK, Orlovsky YI, Wadman EA, Trzaskos JM, Davies P, Decicco CP, Carter PH.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):787-91.

PMID:
15664858
[PubMed - indexed for MEDLINE]
16.

Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.

Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F.

Thromb Haemost. 2005 Sep;94(3):593-8.

PMID:
16268477
[PubMed - indexed for MEDLINE]
17.

III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold.

Kim SH, Anilkumar GN, Zawacki LG, Zeng Q, Yang DY, Shao Y, Dong G, Xu X, Yu W, Jiang Y, Jenh CH, Hall JW 3rd, Carroll CD, Hobbs DW, Baldwin JJ, McGuinness BF, Rosenblum SB, Kozlowski JA, Shankar BB, Shih NY.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):6982-6. doi: 10.1016/j.bmcl.2011.09.120. Epub 2011 Oct 5.

PMID:
22018463
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.

Dobesh PP.

Pharmacotherapy. 2009 Sep;29(9):1089-102. doi: 10.1592/phco.29.9.1089.

PMID:
19698014
[PubMed - indexed for MEDLINE]
19.

Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release.

McIlvain HB, Ma L, Ludwig B, Manners MT, Martone RL, Dunlop J, Kaftan EJ, Kennedy JD, Whiteside GT.

Eur J Pharmacol. 2010 Sep 25;643(2-3):202-10. doi: 10.1016/j.ejphar.2010.06.046. Epub 2010 Jul 13.

PMID:
20621081
[PubMed - indexed for MEDLINE]
20.

Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists.

Morales-Ramos AI, Mecom JS, Kiesow TJ, Graybill TL, Brown GD, Aiyar NV, Davenport EA, Kallal LA, Knapp-Reed BA, Li P, Londregan AT, Morrow DM, Senadhi S, Thalji RK, Zhao S, Burns-Kurtis CL, Marino JP Jr.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6222-6. doi: 10.1016/j.bmcl.2008.09.102. Epub 2008 Oct 2.

PMID:
18926700
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk